Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
Conflicting results have been reported so far in pooled analyses and studies evaluating the optimum duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. However, randomized clinical trials dedicated to this specific setting of higher thrombotic risk patients have o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2020/6495036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157517443694592 |
|---|---|
| author | Monica Verdoia Cyril Camaro Elvin Kedhi Marco Marcolongo Harry Suryapranata Giuseppe De Luca |
| author_facet | Monica Verdoia Cyril Camaro Elvin Kedhi Marco Marcolongo Harry Suryapranata Giuseppe De Luca |
| author_sort | Monica Verdoia |
| collection | DOAJ |
| description | Conflicting results have been reported so far in pooled analyses and studies evaluating the optimum duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. However, randomized clinical trials dedicated to this specific setting of higher thrombotic risk patients have only recently been completed, pointing at the noninferiority of a shorter strategy as compared to the traditional 12-month DAPT, furthermore allowing to reduce the risk of major bleeding complications. Therefore, a reconsideration of current clinical practice and guidelines should be certainly be advocated in light of the most recent updates, especially among ACS patients treated with percutaneous coronary intervention (PCI) and modern drug-eluting stents (DES). Our aim was to provide a comprehensive review of the available evidence on the optimal DAPT duration in ACS patients. |
| format | Article |
| id | doaj-art-355d61e310004486bbdb581a8fd74e31 |
| institution | OA Journals |
| issn | 1755-5914 1755-5922 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-355d61e310004486bbdb581a8fd74e312025-08-20T02:24:08ZengWileyCardiovascular Therapeutics1755-59141755-59222020-01-01202010.1155/2020/64950366495036Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open IssuesMonica Verdoia0Cyril Camaro1Elvin Kedhi2Marco Marcolongo3Harry Suryapranata4Giuseppe De Luca5Division of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, ItalyDepartment of Cardiology, UMC St Radboud, Nijmegen, NetherlandsDivision of Cardiology, AZ Sint Jan, Bruges, BelgiumDivision of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, ItalyDepartment of Cardiology, UMC St Radboud, Nijmegen, NetherlandsDivision of Cardiology, Azienda Ospedaliera-Universitaria “Maggiore della Carità”, Eastern Piedmont University, Novara, ItalyConflicting results have been reported so far in pooled analyses and studies evaluating the optimum duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. However, randomized clinical trials dedicated to this specific setting of higher thrombotic risk patients have only recently been completed, pointing at the noninferiority of a shorter strategy as compared to the traditional 12-month DAPT, furthermore allowing to reduce the risk of major bleeding complications. Therefore, a reconsideration of current clinical practice and guidelines should be certainly be advocated in light of the most recent updates, especially among ACS patients treated with percutaneous coronary intervention (PCI) and modern drug-eluting stents (DES). Our aim was to provide a comprehensive review of the available evidence on the optimal DAPT duration in ACS patients.http://dx.doi.org/10.1155/2020/6495036 |
| spellingShingle | Monica Verdoia Cyril Camaro Elvin Kedhi Marco Marcolongo Harry Suryapranata Giuseppe De Luca Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues Cardiovascular Therapeutics |
| title | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| title_full | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| title_fullStr | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| title_full_unstemmed | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| title_short | Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues |
| title_sort | dual antiplatelet therapy duration in acute coronary syndrome patients the state of the art and open issues |
| url | http://dx.doi.org/10.1155/2020/6495036 |
| work_keys_str_mv | AT monicaverdoia dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues AT cyrilcamaro dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues AT elvinkedhi dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues AT marcomarcolongo dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues AT harrysuryapranata dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues AT giuseppedeluca dualantiplatelettherapydurationinacutecoronarysyndromepatientsthestateoftheartandopenissues |